Ascendis Pharma A/S
ASND
273 hedge funds and large institutions have $14.3B invested in Ascendis Pharma A/S in 2026 Q1 according to their latest regulatory filings, with 34 funds opening new positions, 108 increasing their positions, 106 reducing their positions, and 58 closing their positions.
477% more call options, than puts
Call options by funds: $341M | Put options by funds: $59M
33% more funds holding in top 10
Funds holding in top 10: 12 → 16 (+4)
4% more capital invested
Capital invested by funds: $13.8B → $14.3B (+$537M)
2% more repeat investments, than reductions
Existing positions increased: 108 | Existing positions reduced: 106
3.9% less ownership
Funds ownership: 104.44% → 100.54% (-3.9%)
10% less funds holding
Funds holding: 302 → 273 (-29)
41% less first-time investments, than exits
New positions opened: 34 | Existing positions closed: 58
Top Buyers
Top Sellers
ASND Hedge Fund Activity: Q1 2026 in Review
273 of the 8,126 institutional investors tracked by Wall St. Rank reported a position in Ascendis Pharma A/S (ASND) for Q1 2026, worth a combined $14.3B — up 3.9% from $13.8B a quarter earlier.
Sellers outnumbered buyers: 58 funds closed out of ASND and 34 opened new positions — a net loss of 24 holders — while 106 trimmed existing stakes and 108 added.
The largest buyer was T. Rowe Price Investment Management, adding an estimated $1.01B. The largest seller was Janus Henderson Group, exiting entirely with an estimated $866M sold.
- 273 institutional investors held Ascendis Pharma A/S (ASND) as of Q1 2026, down from 302 in Q4 2025.
- Funds reported $14.3B of Ascendis Pharma A/S stock for Q1 2026, up 3.9% quarter-over-quarter.
- 34 funds opened new Ascendis Pharma A/S positions in Q1 2026 and 58 closed out, a net change of -24 holders.
- The largest Ascendis Pharma A/S buyer in Q1 2026 was T. Rowe Price Investment Management, an estimated $1.01B added.
- The largest Ascendis Pharma A/S seller in Q1 2026 was Janus Henderson Group, an estimated $866M sold.
Based on aggregated 13F filings for Q1 2026.